

The patient journey

References

1. Fields, Michael E., et al. How to select patients for lead extraction. *Heart Rhythm*, Vol 4, Issue 7, July 2007.
2. Voight, Andrew, et al. Rising Rates of Cardiac Rhythm Management Device Infections in the United States: 1996 through 2003. *JACC* Vol. 48, No. 3, 2006: 590-1.
3. Kleeman Thomas, et al. Annual Rate of Transvenous Defibrillation Lead Defect in Implantable Cardioverter-Defibrillators over a Period of >10 Years. *Circulation* 2007; 115:2474-2490.
4. Millennium Research Group, Global Markets for Cardiac Rhythm Management Devices 2013
5. Medtronic CRDM Product Performance Report, Mar 2013. Eucomed (2012)
6. Boston Scientific CRM Product Performance Report, Q1 2013. Eucomed (2012)
7. St. Jude Medical CRM Product Performance Report, Apr 2013. Eucomed (2012)
8. Biotronik Product performance Report, July 2013. Kleeman Thomas, et al. Annual Rate of Transvenous Defibrillation Lead Defect in Implantable Cardioverter-Defibrillators over a Period of >10 Years. *Circulation* 2007; 115:2474-2490.
9. Hauser, Robert, et. al., The Increasing Hazard of Sprint Fidelis Implantable Cardioverter-Defibrillator Lead Failure, *Heart Rhythm*, Vol. 6, No 5, May 2009.
10. Worley, Seth J. Implant Venoplasty: Dilation of Subclavian and Coronary Veins to Facilitate Device Implantation: Indications, Frequency, Methods, and Complications. *Journal of Cardiovascular Electrophysiology* Vol. 19, No. 9, September 2008, 1004-7.
11. Epstein, Laurence, et al. Letter to the Editor Superior Vena Cava Defibrillator Coils Make Transvenous Lead Extraction More Challenging and Riskier. *JACC* Vol. 61, No. 9, 2013. March 5, 2013:985-91
12. Greenspon AJ, Patel JD, Lau E, et al. 16-Year Trends in the Infection Burden for Pacemakers and Implantable Cardioverter-Defibrillators in the United States: 1993 to 2008. *J Am Coll Cardiol*. 2011;58(10):1001-1006. doi:10.1016/j.jacc.2011.04.033.
13. Romeyer-Bouchard, Cécile, Antoine Da Costa, Virginie Dauphinot, Marc Messier, Laurence Bisch, Bernard Samuel, Patrick Lafond, Philippe Ricci, and Karl Isaaz Prevalence and risk factors related to infections of cardiac resynchronization therapy devices *Eur Heart J* (2010) 31 (2): 203-210 first published online October 28, 2009 doi:10.1093/eurheartj/ehp421
14. Margey, R. et al. Contemporary management of and outcomes from cardiac device related infections *Europace* (2010) 12 (1): 64-70 first published online November 11, 2009 doi:10.1093/europace/eup362
15. Lekkerkerker JC, van Nieuwkoop C, Trines SA, van der Bom JG, Bernards A, van de Velde ET, Bootsma M, Zeppenfeld K, Jukema JW, Borleffs JW, Schalij MJ, van Erven L. Risk factors and time delay associated with cardiac device infections: Leiden device registry *Heart*. 2009;95:715–720 doi:10.1136/hrt.2008.151985
16. Voigt, A., et al. (2006). Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. *JACC*, 48(3), 590-591.
17. Kusumoto et al. 2017 HRS Expert Consensus Statement on Cardiovascular Implantable Electronic Device Lead Management and Extraction. *Heart Rhythm*, 2017.
18. D016929-02 Extraction Considerations for Silicone Riata Leads. On file at Philips.
19. Taken directly from "Design of Pacemaker and ICD Leads and Implications for Extraction" by Cooper at UPenn 7/2010
20. St Jude Medical Riata Defibrillation Leads Product Performance Information, St Jude Website , Downloaded August 19, 2013:<http://professional.sjm.com/resources/product-performance/riata-important-info/physician-information/direct-to-physician>
21. Sprint Fidelis Lead Performance information, physician communication, Downloaded 12/14/2013 <http://www.medtronic.com/product-advisories/physician/sprint-fidelis/6949-LEAD-PERFORMANCE>
22. Lovelock JD et al. Generator exchange is associated with an increased rate of Sprint Fidelis lead failure, *Heart Rhythm* 2012 Oct;9(10):1615-8. doi: 10.1016/j.hrthm.2012.06.009. Epub 2012 Jun 6.

23. Goyal, SK., Ellis, CR, Rottman, JN, Whalen, SP, et al. (2013) Lead Thrombi Associated with Externalized Cables on Riata ICD leads: A Case Series, abstract, Journal of Cardiovascular Electrophysiology
24. Ricciardi D, et al; A case of in vivo thrombogenicity of an externalized Riata ST lead, Europace. 2013 Mar;15(3):428. doi: 10.1093/europace/eus395
25. Cheung JW, et.al. Mechanisms, predictors, and trends of electrical failure of Riata leads. Heart Rhythm. 2013 Jun 21. pii: S1547-5271(13)00656-5. doi: 10.1016/j.hrthm.2013.06.015. [Epub ahead of print]
26. Byrd, CL, et al. Intravascular extraction of problematic or infected permanent pacemaker leads: 1994-1996. U.S. Extraction Database, MED Institute. PACE 1999; 22:1348-1357.
27. Pokorney et al. Outcomes Associated with Extraction versus Capping and Abandoning Pacing and Defibrillator Leads Circulation 2017 Oct 10;136(15):1387-1395. doi: 10.1161/CIRCULATIONAHA.117.027636. Epub 2017 Aug 22.
28. Hussein et al. Microbiology of Cardiac Implantable Electronic Device Infections. J Am Coll Cardiol EP 2016;2:498–505 Circ Arrhythm Electrophysiol.
29. Sohal, M. et al. (2014). Laser lead extraction to facilitate cardiac implantable electronic device upgrade and revision in the presence of central venous obstruction. Europace, 16(1), 81-87.
30. Oginosawa Y, Abe H, Nakashima Y. The incidence and risk factors for venous obstruction after implantation of transvenous pacing leads. Pacing Clin Electrophysiol 2002;25:1605–1611.
31. Kutarski, A., Pietura, R., Młynarczyk, K., Małecka, B., & Głowniak, A. (2012). Pacemaker lead extraction and recapture of venous access: technical problems arising from extensive venous obstruction. Cardiology journal, 19(5), 513-517.
32. de Cock CC, et al. Long-term outcome of patients with multiple (> or = 3) noninfected leads: a clinical and echocardiographic study. PACE, Vol 23, No 4, 2000, 423-6
33. Mattei, E., Gentili, G., Censi, F., Triventi, M. and Calcagnini, G. (2015), Impact of capped and uncapped abandoned leads on the heating of an MR-conditional pacemaker implant. Magn Reson Med, 73: 390–400. doi: 10.1002/mrm.25106
34. Kalin R, Stanton MS. Current clinical issues for MRI scanning of pacemaker and defibrillator patients. PACE. April 2005;28(4):326-328.
35. Sohal, Manav, et al. "Laser lead extraction to facilitate cardiac implantable electronic device upgrade and revision in the presence of central venous obstruction." Europace (2013).
36. Epstein, Laurence- Managing Venous Occlusions Presentation, on file w/ Spectranetics
37. Kalin R, Stanton MS. Current clinical issues for MRI scanning of pacemaker and defibrillator patients. PACE. April 2005;28(4):326-328.
38. Bohm, Adam, et al. Complications Due to Abandoned Noninfected Pacemaker Leads. PACE, Vol 24, No 12, 2001, 1721-1724.
39. Wilkoff, Bruce, L., et al. Pacemaker Lead Extraction with the Laser Sheath: Results of the Pacing Lead Extraction with Excimer Sheath (PLEXES) Trial. JACC, Vol 33, No. 6, May 1999.
40. Byrd, Charles, et al. Clinical Study of the Laser Sheath for Lead Extraction: The Total Experience in the United States. Journal of Pacing and Electrophysiology. Vol 125, No. 5, May 2002.
41. Wazni, O et. al. Lead Extraction in the Contemporary Setting: The LEXIcon Study: A Multicenter Observational Retrospective Study of Consecutive Laser Lead Extractions, J Am Coll Cardiol, 55:579-586.
42. Ryan Azarrafiy, BA; Darren C. Tsang, BS; Bruce L. Wilkoff, MD, FHRS; Roger G. Carrillo, MD, MBA, FHRS. The Endovascular Occlusion Balloon for Treatment of Superior Vena Cava Tears During Transvenous Lead Extraction: A Multi-Year Analysis and An Update to Best Practice Protocol. Circulation: Arrhythmia and Electrophysiology, August 2019.
43. Document on file D027561. When deployed, the Bridge occlusion balloon reduces blood loss by up to 90%, on average, in an animal model of an SVC tear. Testing was conducted in a heparinized porcine model which has shorter SVC length than is typical in humans. A balloon design scaled for use specifically in the porcine model was used in generating this data.
44. Document on file, D026197. In an animal model with SVC tears up to 3.5 cm, with 2 pacing leads and 1 ICD lead.